Adenosquamous Lung Carcinoma
Associated Genetic Biomarkers
NCI Definition: An aggressive carcinoma with a poor prognosis characterized by a presence of both malignant squamous cells and glandular cells. 
Adenosquamous lung carcinomas most frequently harbor alterations in TP53, KRAS, EGFR, PIK3CA, and CDKN2A .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, KRAS Mutation, and KRAS Exon 2 Mutation are the most common alterations in adenosquamous lung carcinoma .
There is 1 clinical trial for adenosquamous lung carcinoma, of which 1 is open and 0 are completed or closed. Of the trial that contains adenosquamous lung carcinoma as an inclusion criterion, 1 is phase 1 (1 open).
Autologous genetically-modified mage-a4 c1032 t cells is the most common intervention in adenosquamous lung carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.